Oppenheimer Maintains Incyte(INCY.US) With Buy Rating, Cuts Target Price to $81
Vertex Pharmaceuticals Analyst Ratings
Wells Fargo Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,125
Barclays Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,200
Analysts' Opinions Are Mixed on These Healthcare Stocks: Align Tech (ALGN) and Gilead Sciences (GILD)
Hold Rating on Gilead Sciences Amidst Q2 Revenue Shortfall and Competitive Pressures
BioMarin Pharmaceutical Price Target Maintained With a $89.00/Share by Canaccord Genuity
Biomarin Pharmaceutical Analyst Ratings
Jefferies Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $85
CCORF Maintains Biomarin Pharmaceutical(BMRN.US) With Hold Rating, Cuts Target Price to $89
Neurocrine Biosciences Analyst Ratings
Analysts' Opinions Are Mixed on These Healthcare Stocks: Healthequity (HQY), Community Health (CYH) and Gilead Sciences (GILD)
Barclays Maintains Gilead Sciences(GILD.US) With Hold Rating, Maintains Target Price $76
Leerink Upgrades Ionis to Outperform, Cites Angelman Drug
Leerink Partners Upgrades Ionis Pharmaceuticals(IONS.US) to Buy Rating, Announces Target Price $62
Regeneron Pharma Price Target Raised to $1200.00/Share From $1030.00 by TD Cowen
Vertex Pharmaceuticals Analyst Ratings
Regeneron Pharmaceuticals Analyst Ratings
Ionis Pharmaceuticals Price Target Raised to $68.00/Share From $67.00 by B of A Securities
A Quick Look at Today's Ratings for Ionis Pharmaceuticals(IONS.US), With a Forecast Between $48 to $82